{"id":"W2514555365","doi":"10.1200/jco.2012.30.15_suppl.tps8112","title":"ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Internal medicine; Refractory (planetary science); Multiple myeloma; Progression-free survival; Phases of clinical research; Gastroenterology; Tolerability; Urology; Surgery; Oncology; Clinical trial; Chemotherapy; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00235201,0.002628314,0.002255081,0.0005770526,0.0004646057,0.001374211,0.00176797,0.002027218,0.007570912],"category_scores_gemma":[0.001191889,0.0008185324,0.001453376,0.0004811658,0.001434712,0.001652566,0.0006467944,0.004215002,0.001513768],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001219467,"about_ca_system_score_gemma":0.001456334,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00106947,"about_ca_topic_score_gemma":0.00280982,"domain_scores_codex":[0.9994448,0.0002950029,0.00002308791,0.00008821717,0.00003482848,0.0001140819],"domain_scores_gemma":[0.999297,0.0001254447,0.000133176,0.0000536915,0.00003737651,0.0003532633],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9446635,0.02066198,0.001227226,0.0005515879,0.000592919,0.0001168808,0.0001071479,0.0007170063,0.006224265,0.0001950999,0.002383549,0.02255894],"study_design_scores_gemma":[0.9420893,0.05498062,0.001128692,0.0000157713,0.0001713393,0.00005891391,0.00001881431,0.0002978762,0.0003893259,0.0001030449,0.0007346442,0.00001156956],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9769657,0.003584104,0.0009666657,0.001429633,0.0004748164,0.008983335,0.0036978,0.000377449,0.003520447],"genre_scores_gemma":[0.9654229,0.002762421,0.003673446,0.003197194,0.0005654199,0.01181334,0.00631779,0.00008022213,0.006167302],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007570912,"threshold_uncertainty_score":0.02532727,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2741734888740753,"score_gpt":0.5310445704647311,"score_spread":0.2568710815906558,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}